This is a research study for men and women over the age of 18 who have Acute Hepatitis C Virus Infection. 

This research study will use a study drug called glecaprevir/pibrentasvir (G/P). It contains two drugs for treating hepatitis in one pill. G/P belongs to a group of drugs called direct-acting antiviral agents (DAAs) and prevents the disease from multiplying and spreading in the human body. 

G/P is approved by the U. S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis HCV without or with cirrhosis (scarring of the liver), but has not been approved to treat Acute Hepatitis C Infection.

Participants will take G/P for 8 weeks and total study participation will last approximately 12 weeks.